Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 12:35:52 2024-05-06 pm EDT			5-day change	1st Jan Change
85.08 ^USD	-0.20%		-0.71%	+11.92%

May. 01	Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing	MT
Apr. 30	Edwards Lifesciences Insider Sold Shares Worth $622,062, According to a Recent SEC Filing	MT

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

April 25, 2024 at 04:15 pm EDT

Edwards Lifesciences Corporation revised earnings guidance for the full year 2024. For the year, the company now expects full-year 2024 sales growth to be at the high end of the prior guidance of 8% to 10% and $6.3 billion to $6.6 billion.

Latest news about Edwards Lifesciences Corporation

Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing	May. 01	MT
Edwards Lifesciences Insider Sold Shares Worth $622,062, According to a Recent SEC Filing	Apr. 30	MT
Bernstein Adjusts Price Target on Edwards Lifesciences to $73 From $72	Apr. 29	MT
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $89 From $92	Apr. 26	MT
Stifel Adjusts Price Target on Edwards Lifesciences to $85 From $83	Apr. 26	MT
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $99 From $94	Apr. 26	MT
UBS Adjusts Edwards Lifesciences Price Target to $95 From $92, Maintains Neutral Rating	Apr. 26	MT
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $88 From $85	Apr. 26	MT
Canaccord Genuity Trims Price Target on Edwards Lifesciences to $85 From $86	Apr. 26	MT
Well, it isn't as bad as feared...	Apr. 26
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength	Apr. 25	RE
Transcript : Edwards Lifesciences Corporation, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Edwards Lifesciences Q1 Adjusted Earnings, Net Sales Increase, Q2 Guidance Set	Apr. 25	MT
Earnings Flash (EW) EDWARDS LIFESCIENCES CORPORATION Posts Q1 EPS $0.66, vs. Street Est of $0.64	Apr. 25	MT
Earnings Flash (EW) EDWARDS LIFESCIENCES CORPORATION Reports Q1 Revenue $1.6B, vs. Street Est of $1.57B	Apr. 25	MT
Edwards Lifesciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024	Apr. 25	CI
Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter of 2024	Apr. 25	CI
Edwards Lifesciences Corporation: The story continues	Apr. 23
Baird Adjusts Edwards Lifesciences Price Target to $102 From $100	Apr. 17	MT
Leerink Partners Adjusts Edwards Lifesciences' Price Target to $93 From $96, Keeps Market Perform Rating	Apr. 17	MT
Market sentiment sours	Apr. 16
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
Zacks Investment Research Adjusts Price Target on Edwards Lifesciences to $95 From $97	Apr. 15	MT
Truist Securities Adjusts Edwards Lifesciences Price Target to $105 From $97, Buy Rating Kept	Apr. 15	MT

Chart Edwards Lifesciences Corporation

Duration

Period

More charts

Company Profile

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-07 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Edwards Lifesciences Corporation: The story continues

April 23, 2024 at 11:25 am EDT

More Strategies

Ratings for Edwards Lifesciences Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

85.25 USD

Average target price

95.24 USD

Spread / Average Target

+11.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
EDWARDS LIFESCIENCES CORPORATION	+11.92%	51.37B
THERMO FISHER SCIENTIFIC	+8.46%	218B
DANAHER CORPORATION	+7.62%	184B
INTUITIVE SURGICAL, INC.	+13.29%	135B
SIEMENS HEALTHINEERS AG	+0.04%	62.38B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.76%	50.9B
AGILENT TECHNOLOGIES, INC.	+1.17%	40.87B
GE HEALTHCARE TECHNOLOGIES INC.	+2.35%	36.28B
RESMED, INC.	+26.28%	31.88B
PHILIPS NV	+17.86%	24.39B

Other Advanced Medical Equipment & Technology